Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SEPN
SEPN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SEPN News
Septerna, Inc. Q4 Earnings Exceed Expectations
17h ago
seekingalpha
Septerna Reports Positive Phase 1 Results for SEP-631 in Mast Cell-Driven Diseases
Mar 02 2026
NASDAQ.COM
Positive Phase 1 Results for SEP-631 in Chronic Urticaria
Mar 01 2026
Newsfilter
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
Feb 02 2026
Benzinga
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
Jan 09 2026
renaissancecapital
Septerna Appoints Mark A. Wilson as Chief Legal Officer to Enhance Governance
Jan 08 2026
Globenewswire
Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street
Dec 23 2025
Benzinga
Septerna CEO to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Dec 17 2025
Globenewswire
Wells Fargo Raises Rating on Septerna (SEPN)
Nov 15 2025
NASDAQ.COM
Wells Fargo Boosts Septerna Rating to Overweight and Increases Price Target to $28
Nov 14 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Septerna, Increases Price Target to $30
Nov 11 2025
Benzinga
Moderna (MRNA) Shows Promise: Will Its 13.9% Surge Lead to Further Gains?
Oct 31 2025
NASDAQ.COM
Arcturus Therapeutics (ARCT) Rises 7.7%: Can This Momentum Continue?
Oct 22 2025
NASDAQ.COM
Are Options Traders Anticipating a Significant Shift in Septerna Stock?
Oct 03 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for Septerna, Keeps $26 Price Target Intact
Aug 21 2025
Benzinga
The Implied Analyst 12-Month Target For AVSC
Jul 11 2025
NASDAQ.COM
Show More News
